Comparison · NCT02616146-sae
ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: serious adverse events. Trial comparisons, record NCT02616146-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02616146-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00532 | 0.0027 | 0.0105 | wilson | |
| Risk in group 2 | 0.0061 | 0.00208 | 0.0178 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000778 | -0.0127 | 0.00575 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.872 | 0.232 | 3.28 | log | |
| Odds ratio, group 1 over group 2 | 0.872 | 0.23 | 3.3 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on ENG-E2 125 μg/300 μg than on LNG-EE 150 μg/30 μg | 1,280 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ENG-E2 125 μg/300 μg | Participants were to receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle was to consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days. | 8 | 1,504 | EG000 |
| Group 2 | LNG-EE 150 μg/30 μg | Participants were to receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle was to consist of one tablet per day for 21 days, followed a 7-day tablet-free interval. | 3 | 492 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 1 year
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)
- NCT number
- NCT02616146
- Phases
- PHASE3
- Conditions
- Contraception
- Interventions
- ENG-E2 125 μg/300 μg vaginal ring, LNG-EE 150 μg/30 μg COC
- Lead sponsor
- Organon and Co
- Results first posted
- 2019-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02616146?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02616146-sae